news

Method for inhibiting tumour growth enzyme discovered

A new study has found a novel way to target an enzyme involved in cancer growth, which could inform therapeutics for the condition.

dna tumour growth

Researchers have identified a new way to inhibit an enzyme involved in cancer, which may avoid the toxicity of previous approaches. The enzyme ribonucleotide reductase acts as a bottleneck for tumour growth. According to the study’s authors, the findings could inform focused drug delivery efforts.

The investigation was conducted by researchers from Winship Cancer Institute of Emory University, Atlanta.

Ribonucleotide reductase is vital for cancer growth as it converts RNA ribonucleotides into DNA building blocks. Several chemotherapy drugs inhibit ribonucleotide reductase through a different mechanism.

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

The researchers found that RRM2, one of ribonucleotide reductase’s two sections, is regulated by a tag called acetylation. They also identified another enzyme called Kat7 that adds that same tag. At a particular site, acetylation inactivates RRM2 by preventing the individual molecules from pairing up.

“Based on our findings, we will develop novel anticancer agents that inhibit ribonucleotide reductase activity by directly regulating RRM2 acetylation in cancer cells,” says Xingming Deng, lead researcher.

In addition, the team observed that Sirt2, an enzyme that removes acetylation from RRM2 and activates it, is more abundant in samples from lung cancer patients. The team suggest that Sirt2 could be a prognostic biomarker for lung cancer.

The results were published in Nature Communications.

Leave a Reply

Your email address will not be published. Required fields are marked *